Full-Time

SAP VISTEX Change Manager

Business System Analyst

Posted on 10/31/2025

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Category
IT & Security (4)
, , ,
Required Skills
SAP Products
Requirements
  • Doctorate degree / Master's degree / Bachelor's degree and 8 to 13 years Information Systems experience
  • 5 years experience as Change Manager for Vistex environments
  • 5 years experience as Business System Analyst Order to Cash business process integration with Vistex environments
  • Strong knowledge in SAP SD Pricing, SAP OTC flow, Vistex Contract Management solution, Master Data Concepts, SAP ABAP Development (preferably on Vistex Module)
  • Demonstrated experience in Vistex topics: Price proposal, Contract Management, Approval Status Flow, Proforma & Price Simulation & Order execution, Deals, Composite Rebates, Claims, Claw back, Health Insurance, Settlements
  • Be able to multitask, balance improvements, help with issue resolutions, support the global architect lead on designs for larger projects and support/lead pilots for new tools
  • Strong analytical and problem-solving skills
  • Solid understanding of business complexity and project inter-dependencies
  • Be a great teammate who is able to work optimally at all levels of an organization with the ability to influence others to move toward consensus
  • Fluent in English, both in oral and written communication
  • Experience in supporting and leading projects / improvement initiatives
  • Soft Skills: “Can do” mentality / ownership to make it happen
  • Soft Skills: Pro-active / committed
  • Soft Skills: Positive mind-set and influence on the team
  • Soft Skills: Strong problem-solving skills
  • Soft Skills: Result driven
  • Soft Skills: Strong quality attitude
  • Soft Skills: Accurate and very detailed attitude
  • Soft Skills: Good communication which includes written and verbal communications as well as visualizations
Responsibilities
  • Support the Amgen Vistex product team design solutions that best fit business needs.
  • Provide consultation to application owners and business partners regarding short and long-range architecture solutions to meet business imperatives
  • Recommend solutions and develop case alternatives which anticipate the future direction of the business, its drivers and technology strategy. Enthusiastically facilitate complex design and technical discussions, balancing different opinions and drive towards decisions
  • Support and deliver the translation of business process, master data and standard methodology requirements into executable design and work
  • Support and deliver root cause analysis and drive resolution of incidents raised by the business
  • Support and deliver project and improvement assessments of feasibility, impact and effort required to implement changes to or extensions of the global SAP Vistex template in response to business requirements
  • Ensure solutions developed across functions are aligned to enterprise architecture standards and principles
  • Support and deliver creation of business architecture models demonstrating how products, operations and systems interoperate within the organization
Desired Qualifications
  • Experience working with Agile and DevOps
  • Experience working with Jira
  • Be open to work in a dynamic environment embracing change as a constant and adopting new technologies
  • Work in global teams and matrix organizations
  • Able to follow through on tasks and motivate others to meet deadlines.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Tarlatamab wins China NMPA approval May 2026 for $2B+ sales potential.
  • Q1 2026 revenues hit $8.6B with 16 brands posting double-digit growth.
  • Zai Lab partners on DLL3-ADC plus IMDELLTRA for SCLC trials.

What critics are saying

  • Prolia sales drop 34% to $727M from biosimilar competition in Q1 2026.
  • FDA warns Tavneos causes liver injuries, proposes approval withdrawal.
  • Horizon drugs Tepezza, Uplizna, Krystexxa underperform 19 months post-acquisition.

What makes Amgen unique

  • Amgen's BiTE platform establishes IMDELLTRA as second-line SCLC standard.
  • MariTide advances in Phase III obesity trials with monthly dosing.
  • UPLIZNA surges 73% post-IgG4 and gMG approvals in 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Apr 3rd, 2026
Amgen faces Tavneos liver injury warning as Zai Lab oncology collaboration expands IMDELLTRA pipeline

Amgen faces fresh safety concerns after the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Tavneos (avacopan) in late March 2026. The development adds regulatory risk to the company's investment profile. Separately, Zai Lab announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, underscoring the company's ongoing oncology expansion through external partnerships. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. However, pessimistic analysts model revenues slipping to $34.4 billion with earnings near $5.2 billion, reflecting concerns around pricing pressure, biosimilar competition and rising research and development spend alongside the new safety issues.

Yahoo Finance
Mar 30th, 2026
Amgen stock up 24% since Jim Cramer's June recommendation, beats earnings estimates

Amgen, one of the world's largest pharmaceutical companies, has seen its shares rise 24% since Jim Cramer discussed the stock on Mad Money in June 2025. The company is currently developing the weight loss drug MariTide. Amgen's shares jumped 7.5% in November 2025 after posting third-quarter results that beat analyst expectations, with $9.6 billion in revenue and $5.64 earnings per share against forecasts of $8.98 billion and $5.04 respectively. In February 2026, shares rose 8% following fourth-quarter earnings that also exceeded estimates. Cramer expressed cautious optimism about the biotech company, noting its mid-single-digit earnings growth and potential upside from its GLP-1 drug development. Whilst calling Eli Lilly his preferred GLP-1 play, Cramer said investors "could do a lot worse than Amgen" for a bargain option.

Yahoo Finance
Mar 25th, 2026
Wells Fargo lifts Amgen price target to $390, cites $20B myasthenia gravis market potential by 2036

Wells Fargo has raised its price target on Amgen to $390 from $375, maintaining an Equal Weight rating. The firm cited emerging therapies including CD20, BAFF/APRIL and next-generation complement inhibitors as potential drivers that could expand the generalized myasthenia gravis market threefold over the next decade, potentially reaching $15 billion in US sales and $20 billion globally by 2036. Separately, Jefferies initiated coverage on Amgen with a Hold rating and $350 price target on 10 March, noting the stock has gained approximately 35% over the past six months. Last month, Amgen reported fourth-quarter adjusted earnings per share of $5.29, beating the $4.76 consensus estimate, on revenue of $9.9 billion versus $9.45 billion expected.

Yahoo Finance
Mar 15th, 2026
Amgen joins TrumpRx discount scheme and lifts dividend to $2.52 per share

Amgen has announced a $2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs including Amjevita, Aimovig and Repatha. The company is also preparing for its 11 March presentation at the Leerink Global Healthcare Conference in Miami. The moves come alongside double-digit revenue and earnings per share growth in 2025 and advances in obesity and oncology programmes. However, the TrumpRx discounting could pressure net pricing as Amgen invests heavily in late-stage trials and manufacturing expansion. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. Some analysts see a tougher outlook, with revenue potentially drifting towards $34.4 billion and earnings around $5.2 billion.

INACTIVE